HUDDINGE, Sweden--(BUSINESS WIRE)--Regulatory News: Medivir AB (STO:MVIRB), an emerging research-based specialty pharmaceutical company focused on infectious diseases, today announces several new appointments to its executive management team. Ron Long, CEO of Medivir commented, “These appointments will support Medivir as it continues to progress its research and commercial capabilities and will provide the company with a stronger operational and strategic management team to develop Medivir’s existing R&D projects and marketed products”.
